ICG vs CANF vs RCUS vs BTBT

For growth investors, Bit Digital, Inc.

(BTBT) is the stronger pick with 264. 6% revenue growth year-over-year, versus -9. 3% for Can-Fite BioPharma Ltd. (CANF). Intchains Group Limited (ICG) offers the better valuation at 5. 2x trailing P/E (2. 8x forward), making it the more compelling value choice. Analysts rate Intchains Group Limited (ICG) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Intchains Group Limited (ICG) is the cheapest at 5.

2x versus Bit Digital, Inc. at 9. 2x.

Over the past 5 years, Arcus Biosciences, Inc.

(RCUS) delivered a total return of -18. 6%, compared to -84. 6% for Bit Digital, Inc. (BTBT). Over 10 years, the gap is even starker: RCUS returned +45. 9% versus CANF's -99. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Can-Fite BioPharma Ltd.

(CANF) is the lower-risk stock at 0. 88β versus Bit Digital, Inc. 's 3. 37β — meaning BTBT is approximately 282% more volatile than CANF relative to the S&P 500. On balance sheet safety, Intchains Group Limited (ICG) carries a lower debt/equity ratio of 0% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Bit Digital, Inc.

(BTBT) is pulling ahead at 264. 6% versus -9. 3% for Can-Fite BioPharma Ltd. (CANF). On earnings-per-share growth, the picture is similar: Intchains Group Limited grew EPS 490. 9% year-over-year, compared to -4. 8% for Arcus Biosciences, Inc.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Intchains Group Limited (ICG) is the more profitable company, earning 18.

3% net margin versus -1169. 1% for Can-Fite BioPharma Ltd. — meaning it keeps 18. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BTBT leads at 16. 8% versus -1206. 2% for CANF. At the gross margin level — before operating expenses — CANF leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ICG: 205.

3% to $4. 00.

In this comparison, BTBT (0.

3% yield) pays a dividend. ICG, CANF, RCUS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Can-Fite BioPharma Ltd.

(CANF) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 88)). Bit Digital, Inc. (BTBT) carries a higher beta of 3. 37 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CANF: -99. 1%, BTBT: -60. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ICG (Technology) and CANF (Healthcare) and RCUS (Healthcare) and BTBT (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ICG is a small-cap high-growth stock; CANF is a small-cap quality compounder stock; RCUS is a small-cap quality compounder stock; BTBT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.